Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,922 recruiting studies in this area right now.
By phase
- Not applicable2,026
- Phase 21,073
- Phase 1790
- Phase 1/Phase 2479
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,922 total
- NCT07191119Recruiting
Nerve stimulation for insomnia in childhood leukemia survivors
This study tests a small, wearable device that gently stimulates a nerve in your ear (called the vagus nerve) to help with insomnia. It's designed for adult survivors of childhood leukemia who still have trouble sleeping.
Memphis, TennesseeAges 20–50 - NCT07188090RecruitingPhase 2
Mozobil for stem cell transplant study
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07185503Recruiting
Testing two antifungal drugs for mucormycosis with blood cancer
This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.
DalianAges 18–65 - NCT07185633RecruitingPhase 2
Study of Gecacitinib and Steroids for Acute Graft-Versus-Host Disease
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
Suzhou, JiangsuAges 18 years+ - NCT07186179Recruiting
Stem cell mobilization for diamond blackfan anemia
This trial tests whether a medication can help move your own blood stem cells from your bone marrow into your bloodstream, so they can be collected. This is a first step toward possibly using those cells in a future treatment for diamond blackfan anemia.
New Hyde Park, New YorkAges 3–30 - NCT07190079Recruiting
New way to diagnose blood clots in the lungs using saline
This study tests a new method using a saline solution and a special imaging belt to quickly diagnose pulmonary embolism (a blood clot in the lungs) in people with acute breathing problems. If successful, it could provide a faster, safer alternative to standard CT scans.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07183878Recruiting
Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Hangzhou, ZhejiangAges 12–60 - NCT07187167RecruitingPhase 2
Lenalidomide and dexamethasone for Rosai-Dorfman disease
This trial tests a combination of two drugs, lenalidomide and dexamethasone (called the RD regimen), for people with Rosai-Dorfman disease, a rare disorder that causes immune cells to build up in the body. Researchers want to see if this treatment is safe and effective for patients who are newly diagnosed or whose disease has come back or not improved with other treatments.
BeijingAges 18–80 - NCT05943067RecruitingPhase 1/Phase 2
Test of donor immune cells after stem cell transplant to prevent relapse
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
TübingenAges 2 months–65 years - NCT04184505RecruitingPhase 3
Testing stem cell transplant in higher-risk myelodysplastic syndrome
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
AlessandriaAges 18–70 - NCT07183592Recruiting
Changing IV tubing in the ICU: does less often harm?
This trial compares changing the tubing attached to central lines every 4 days versus every 7 days, to see if less frequent changes cause more infections. If you have a central line in the ICU that will stay in for at least a week, this study may help decide the safest schedule.
Saint-Pierre, La RéunionAges 18 years+ - NCT06061094RecruitingPhase 2
Ph+ ALL chemo with targeted pills and transplant
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
AachenAges 18–65 - NCT07177079RecruitingPhase 1
High-dose vitamin C with standard therapy for newly diagnosed AML
This trial tests adding high-dose vitamin C (ascorbate) to the standard two-drug treatment (azacitidine and venetoclax) for people with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemo. The goal is to see if the vitamin C makes the standard treatment work better and helps control the leukemia.
Iowa City, IowaAges 18–75 - NCT07177300RecruitingPhase 4
Hydroxyurea for sickle cell disease in children
This trial tests different ways to start hydroxyurea for children with sickle cell anemia. The goal is to find the safest and most effective approach to help manage symptoms and prevent complications.
Cincinnati, OhioAges 6 months+ - NCT07176624Recruiting
Early prone positioning and tube feeding in ICU
This study tests whether early prone positioning (lying on your stomach) and early tube feeding can help people with severe lung failure in the ICU recover faster. It's for adults with organ failure and severe ARDS who can safely be placed on their stomach.
Changchun, JilinAges 18 years+ - NCT07183605Recruiting
How different ways of drawing blood from a central line compare for heparin activity
This trial checks whether blood samples taken from a central line using either a syringe flush or a vacuum tube give the same heparin activity results as blood from a vein in the arm. It is designed for patients in the ICU who are on a steady heparin drip.
OrléansAges 18 years+ - NCT07179991Recruiting
DDAVP (desmopressin) for bleeding during heart surgery
This study tests whether a medicine called desmopressin (DDAVP) can reduce bleeding during heart surgery. It uses a special blood test (TEG6) to decide who gets the medicine.
London, OntarioAges 18 years+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07180992Recruiting
Monocytes and CART cell response in multiple myeloma
This trial looks at how certain immune cells (monocytes) affect the success of CART cell therapy for multiple myeloma. It may help doctors improve treatment for future patients.
AmiensAges 18 years+ - NCT07181941RecruitingPhase 1/Phase 2
Testing lower doses of linvoseltamab for multiple myeloma
This trial tests if a lower dose of linvoseltamab can still work well for people with multiple myeloma that has come back or not responded to treatment. It aims to reduce side effects while keeping the cancer under control.
Seattle, WashingtonAges 18 years+ - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07179679RecruitingPhase 1
Study of a new shot for multiple myeloma
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05863234RecruitingPhase 1/Phase 2
Safety study for aggressive NK-cell leukemia patients
This early-phase study tests a new treatment approach for people with aggressive NK-cell leukemia, focusing mainly on safety. It may be offered to patients whose disease matches the study’s specific leukemia diagnosis rules.
Hiroshima, HiroshimaAges 18–70
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,922 recruiting hematology studies from the U.S. registry right now, out of 7,323 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.